GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » Treasury Stock

Healthwell Acquisition I (Healthwell Acquisition I) Treasury Stock : $0.00 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Healthwell Acquisition I Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Healthwell Acquisition I's treasury stock for the quarter that ended in Jun. 2023 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Healthwell Acquisition I Treasury Stock Historical Data

The historical data trend for Healthwell Acquisition I's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healthwell Acquisition I Treasury Stock Chart

Healthwell Acquisition I Annual Data
Trend Dec21 Dec22
Treasury Stock
- -

Healthwell Acquisition I Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Treasury Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Healthwell Acquisition I Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Healthwell Acquisition I (Healthwell Acquisition I) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » Treasury Stock
Comparable Companies
PWUP BLUA CBRG CHAA NNAG TGAA DPCS EGGF PORT CITE PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
1001 Green Bay Road, Suite 227, Winnetka, IL, USA, 60093
Website
https://www.healthwellspac.com
Healthwell Acquisition Corp I is a blank check company.

Healthwell Acquisition I (Healthwell Acquisition I) Headlines

From GuruFocus

Healthwell Acquisition Corp. I Announces the Separate Trading of Its Class A Common Stock and Warrants Commencing September 23, 2021

By Business Wire Business Wire • 09-22-2021

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

By Business Wire • 11-18-2023

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

By Business Wire • 11-04-2023

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

By Business Wire Business Wire • 04-27-2023

Healthwell Acquisition Corp. I Announces New Meeting Date for the Special Meeting of Stockholders to Approve Proposed Business Combination With Starton Therapeutics, Inc. and Related Transactions

By Business Wire • 10-17-2023

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

By Business Wire • 09-13-2023

Starton Therapeutics, Inc. and Healthwell Acquisition Corp. I to Present at the Jefferies Healthcare Conference

By Business Wire Business Wire • 06-06-2023

Healthwell Acquisition Corp. I Announces Closing of $250,000,000 Initial Public Offering

By Business Wire Business Wire • 08-05-2021

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 07-10-2023

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 10-04-2023